UTMB develops a universal vaccine platform that’s cheaper and shelf stable
Researchers at The University of Texas Medical Branch at Galveston have developed a less expensive way to produce vaccines that cuts the cost of vaccine production and storage by 80 percent without decreasing safety or effectiveness. The findings are currently available in EBioMedicine.
Vaccines are the most effective way to prevent and eradicate infectious diseases. Currently, many vaccines have to be manufactured in cell culture or eggs, which is expensive and carries the risk of contaminations. In addition, most vaccines must be kept refrigerated during the transportation from manufacturers to health care clinics. In tropical and subtropical regions, such cold storage requirements could contribute to more than 80 percent of the vaccine cost.
“The ability to eliminate cell culture or eggs and cold storage will change the process of vaccine development,” said UTMB’s Pei-Yong Shi, professor in the department of biochemistry and molecular biology. “Importantly, this vaccine technology could potentially serve as a universal platform for development of live-attenuated vaccines for many viral pathogens.”
To achieve these goals, the UTMB team engineered a live-attenuated Zika vaccine in the DNA form. Once the DNA is delivered into our body, it launches the vaccine in our cells, leading to antibody production and other protective immunity. With this production method, there is no need to manufacture the vaccine in cell culture or eggs at factories. Because DNA molecules are shelf stable, the vaccine will not expire at warm temperatures and could be stockpiled at room temperature for years.
Using UTMB’s Zika vaccine as a model, the research group showed that the DNA platform worked very efficiently in mice. After a single low dose, the DNA vaccine protected mice from Zika virus infection, mother-to-fetus transmission during pregnancy and male reproductive tract infection and damage.
“This is the first study to demonstrate that, after a single low dose, a DNA vaccine could induce saturated protective immunity,” Shi said. “We will continue testing this promising Zika vaccine platform and then apply the platform to other viruses.”
The Latest on: Vaccine production
via Google News
The Latest on: Vaccine production
- Manufacturer to Produce Cell-Based Flu Vaccine for Next Season on April 17, 2019 at 9:58 am
The drug manufacturer has been working with cell-based CVVs since the FDA granted its approval to use them in the production of influenza vaccines, in 2016. Seqirus incorporated a cell-based H3N2 CVV ... […]
- Increasing Awareness about of Varicella Virus Vaccine Market Growth of CAGR with Focusing Key players like GSK, Merck, Sanofi, Green Cross, etc on April 17, 2019 at 3:44 am
It includes several research studies such as manufacturing cost analysis, absolute dollar opportunity, pricing analysis, company profiling, production and consumption analysis, and market dynamics. ... […]
- Emergent BioSolutions Announces Interim Results From Phase 2 Study Evaluating CHIKV-VLP, Chikungunya Virus Vaccine Candidate on April 16, 2019 at 7:42 pm
that could potentially promote a stronger immune response and increased antibody production. Studies have shown that VLP vaccines are highly immunogenic, have a proven safety record, and typically ... […]
- Answers to questions about common vaccine concerns on April 15, 2019 at 12:48 pm
“As a result of these decisions, liability and prices soared, and several vaccine manufacturers halted production,” the CDC’s website states. “A vaccine shortage resulted and public health ... […]
- Dog Vaccine Market 2019: Potential growth, attractive valuation make it is a long-term investment on April 15, 2019 at 6:02 am
The key components in view of which the extent of the Dog Vaccine Market has been evaluated in this report are production volume and revenue in USD. DUBLIN, United States - April 15, 2019 ... […]
- Seqirus Announces Further Advances in Cell-Based Influenza Vaccine Technology on April 15, 2019 at 5:42 am
The manufacturing seeds produced from these CVVs are used to grow large quantities of virus, in either eggs or cells, enabling the mass production of influenza vaccine matched to the WHO ... […]
- BiondVax Universal Flu Vaccine Patent Application Accepted in Australia on April 15, 2019 at 4:50 am
BVXV), announced today that a patent application covering formulation and production processes of the M-001 universal influenza vaccine candidate was accepted in Australia. Titled "Compositions of ... […]
- Porcine Vaccine Market Analysis, Trends & Forecast to 2025| Bayer AG., Bimeda Animal Health, Boehringer Ingelheim GmbH, Ceva Sante Animale on April 15, 2019 at 1:33 am
Global Growth Trends: There are three chapters included in this section, i.e. industry trends, the growth rate of key producers, and production analysis. Porcine Vaccine Market Share by Manufacturer: ... […]
- Homeland Security Ramps Up African Swine Fever Vaccine Research on April 9, 2019 at 8:19 am
“We need a better method,” Rodriguez said. “Part of S&T’s funding is for exploring the existing cell lines to see if we can find any that are promising for vaccine production.” Improved Diagnostic ... […]
via Bing News